Melissa Putman, MD
Endocrinology, Diabetes & Metabolism · Boston, MANPI 1417083122
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,791 of the $23,124 with a category attached, or 76.9%. 4 manufacturers reported payments, led by Sanofi at 52.4% of the total. 2025 is the largest year on record at $14,912, more than ten times the $29 reported in 2019.
Across 21 payments — averaging $1101.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$12K
- Vertex$10K
- Biomarin Pharmaceutical Inc.$492
- Dexcom, Inc.$116
Across 45 payments — averaging $6524.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$232K
- Sequel Med Tech, LLC$57K
- Dexcom, Inc.$5K
What the payments were for
- Consulting fees$17,79177%
- Speaking & faculty fees$3,90517%
- Travel & lodging$7983%
- Food & beverage$6313%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 5 | $12,127 |
| Vertex | 13 | $10,389 |
| Biomarin Pharmaceutical Inc. | 1 | $492 |
| Dexcom, Inc. | 2 | $116 |
How this compares
$23,124 in reported general payments places this provider in the 85th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gvoke Hypopen 2-PackGlucagon | 13 | $8,065 |
| LantusInsulin Glargine,hum.Rec.Anlog | 13 | $845 |
| Levothyroxine Sodium | 18 | $221 |
| Methimazole | 13 | $182 |
| Alendronate Sodium | 21 | $153 |
| Hydrochlorothiazide | 11 | $11 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Boston
- Jason GagliaBoston$2.4M
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Augusto Caballero-RoblesBoston$150K
- Osama HamdyBoston$117K
- Barbara KahnBoston$105K
- Naomi FisherBoston$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.